Faculty Articles

Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent

Publication Title

P&T (Pharmacy & Therapeutics)

Volume

41

Issue

4

Publication Date / Copyright Date

4-1-2016

First Page

222

Last Page

227

Publisher

MediMedia

Abstract

Schizophrenia is a chronic mental illness known as one of the most complex and challenging psychiatric disorders to treat.1 It is a heterogeneous clinical syndrome involving a compilation of cognitive, behavioral, and emotional dysfunctions.2 The mainstay of treatment for schizophrenia is pharmacotherapy, and in many cases it is impossible to implement effective psychosocial rehabilitation without antipsychotic treatment.1 However, one of the difficulties in the treatment of schizophrenia is patient nonadherence to medication regimens, with the percentage of nonadherence reported as 40% to 60% to antipsychotics and 11% to 80% in patients with schizophrenia.3 Many consequences of poor compliance are known, including relapse, hospitalization, exacerbations, behavior harmful to one’s self or others, suicide, and overall negative impacts on patients, their families, and society as a whole.3–4 The most common cause of relapse is poor adherence, with relapse in first-episode patients increasing almost fivefold when antipsychotic drug treatment is discontinued.4–6

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

antipsychotics, Invega Trinza, psychiatry, schizophrenia

Link to Full Text
Peer Reviewed

Find in your library

Share

 
COinS